Replimune Group, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Replimune Group, Inc. (REPL) on September 2, 2025. The filing reports on the results of the Company's Annual Meeting of Stockholders held on September 3, 2025, and the scheduling of a Type A meeting with the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance voting results and regulatory updates.
Material Changes and Voting Results
The following proposals were voted on at the Annual Meeting:
- Proposal 1 (Election of Class I Directors): All five nominees were elected. Michael Goller received the highest support (62,116,691 votes for), while Kapil Dhingra received the most votes withheld (9,767,367).
- Proposal 2 (Ratification of Auditors): The selection of PricewaterhouseCoopers LLP for the fiscal year ending March 31, 2026, was ratified with 70,375,492 votes for.
- Proposal 3 (Say on Pay): Executive compensation for the fiscal year ended March 31, 2025, was approved with 61,212,356 votes for.
- Proposal 4 (Amendment to 2018 Omnibus Incentive Compensation Plan): This proposal was not approved. Stockholders voted 35,490,941 against the amendment compared to 26,965,226 for.
Outlook, Risks, and Unusual Items
Regulatory Update: On September 2, 2025, the Company announced the scheduling of a Type A meeting with the FDA. The specific agenda or timing of this meeting is detailed in the accompanying news release (Exhibit 99.1) but is not explicitly described in the body of this 8-K.
Corporate Governance Risk: The failure of Proposal 4 indicates significant shareholder opposition to the proposed changes in the Company's incentive compensation plan, which may require management to revise its approach to executive and employee equity incentives.
Investor Verification Checklist
- Review the full text of the news release (Exhibit 99.1) to understand the specific purpose and expected outcomes of the scheduled FDA Type A meeting.
- Analyze the reasons behind the rejection of the Omnibus Incentive Compensation Plan amendment to assess potential impacts on future executive retention and equity dilution.
- Monitor subsequent filings for any revised proposals regarding the incentive plan or updates on the FDA meeting status.